公开(公告)号：US20200330442A1

公开(公告)日：2020-10-22

申请号：US16915506

申请日：2020-06-29

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Zelton Dave SHARP ,  Randy STRONG ,  Paul HASTY ,  Carolina LIVI ,  Arlan RICHARDSON

IPC: A61K31/436 ,  A61K31/415 ,  A61K31/192 ,  A61K9/51 ,  A61K45/06

Abstract: Disclosed are methods and compositions for the treatment or prevention of intestinal polyps or prevention of cancer in a patient who has been identified as being at risk for developing intestinal polyps or intestinal cancer. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such inhibitor of the target of rapamycin (TOR).

公开(公告)号：US20200328877A1

公开(公告)日：2020-10-15

申请号：US16845556

申请日：2020-04-10

Applicant: The Board of Regents of the University of Texas System

Inventor： Alekhya MUTHINENI ,  Eugene JOHN

IPC: H04L9/06 ,  G06F1/26

Abstract: The present techniques may provide improved processing and functionality of performance of the 128-bit AES Algorithm, which may provide improved power consumption. For example, in an embodiment, an encryption and decryption apparatus may comprise memory storing a current state matrix of an encryption or decryption process and a plurality of multiplexers configured to receive from the memory current elements of the state matrix stored in the memory, perform a cyclic shift on the received elements of the state matrix, and transmit the shifted elements to the memory for storage as a new state matrix.

公开(公告)号：US20200323879A1

公开(公告)日：2020-10-15

申请号：US16813017

申请日：2020-03-09

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Thomas J. SLAGA ,  Jacob JUNCO ,  Huiyun LIANG ,  Sara REYNA

IPC: A61K31/56 ,  A61K31/19 ,  A61K31/05 ,  A61K9/00

Abstract: Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.

公开(公告)号：US10799466B2

公开(公告)日：2020-10-13

申请号：US16434541

申请日：2019-06-07

Applicant: The Board of Regents of the University of Texas System

Inventor： Phillip C. Phan ,  Allen W. Burton

IPC: A61K9/19 ,  A61K9/08 ,  A61K31/07 ,  A61K31/02 ,  A61K9/00

Abstract: The present invention provides methods for reducing pain in a subject in need of such pain reduction by delivering, e.g., intrathecally or epidurally, a volatile anesthetic such as a halogenated ether compound in an amount effective to reduce pain. Chronic or acute pain may be treated, or the anesthetic may be delivered to the subject to anesthetize the subject prior to a surgery. In certain embodiments, isoflurane, halothane, enflurane, sevoflurane, desflurane, methoxyflurane, xenon, and mixtures thereof may be used. Dosing regimens including a one-time administration, continuous and/or periodic administration are contemplated.

公开(公告)号：US20200306313A1

公开(公告)日：2020-10-01

申请号：US16900178

申请日：2020-06-12

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Senlin LI ,  Robert A. CLARK ,  Cang CHEN

IPC: A61K35/28 ,  A61M1/38 ,  C12N5/0789 ,  A61K31/395 ,  A61K38/19 ,  A61M1/34

Abstract: Certain embodiments are directed to compositions and methods for non-cytotoxic hematopoietic stem cell transplantation.

公开(公告)号：US20200260698A1

公开(公告)日：2020-08-20

申请号：US16639828

申请日：2018-08-17

Applicant: The Board of Regents of the University of Texas System

Inventor： Viktoriia KYRYCHENKO ,  Eric N. OLSON ,  Rhonda BASSEL-DUBY

IPC: A01K67/027 ,  C12N15/10 ,  C12N15/113 ,  A61P21/00

Abstract: CRISPR/Cas9-mediated genome editing holds clinical potential for treating genetic diseases, such as Duchenne muscular dystrophy (DMD), which is caused by mutations in the dystrophin gene and absence or deficiency of dystrophin protein in striated muscle. Provided herein are compositions and methods for treating DMD caused by mutations in the dystrophin Actin Binding Domain 1 (ABD-1). The compositions and method described herein can be used to remove mutant sequences in dystrophin ABD-1 to generate a corrected DMD protein that, while lacking one or more exons (e.g., exons 3-9), retains important functional properties.

公开(公告)号：US10729693B2

公开(公告)日：2020-08-04

申请号：US16288820

申请日：2019-02-28

Applicant: PONCE MEDICAL SCHOOL FOUNDATION, INC. ,  The Board of Regents of the University of Texas System

Inventor： Annelyn Torres-Reveron ,  Caroline B. Appleyard ,  Idhaliz Flores

IPC: C07D487/04 ,  A61K31/519 ,  A61P15/00 ,  A61K31/505

Abstract: The present disclosure provides methods for treating a mammal that has endometriosis using a CHRH1 antagonist composition. In some embodiments, the CHRH1 antagonist is antalarmin or an equivalent.

公开(公告)号：US20200215100A1

公开(公告)日：2020-07-09

申请号：US16702164

申请日：2019-12-03

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Shao-Ling HUANG ,  David MCPHERSON ,  Yong-Jian GENG ,  Xing YIN ,  Hyunggun KIM ,  Melvin KLEGERMAN ,  Tao PENG

IPC: A61K33/00 ,  A61K47/02 ,  A61K47/14 ,  A61K9/00 ,  A61K47/24 ,  A61K9/107 ,  A61K47/44 ,  A23D7/005 ,  A23L33/115 ,  A23L33/16 ,  A23L33/25 ,  A61K47/69 ,  A61J1/14 ,  A61K47/28 ,  A61K47/42

Abstract: Provided herein is a novel composition for oral administration and delivery of Noble gas, such as xenon or argon. Methods of treating and preventing neuronal or cardiovascular damage with such compositions are also provided.

公开(公告)号：US20200207742A1

公开(公告)日：2020-07-02

申请号：US16303043

申请日：2017-06-29

Applicant: Bruce BEUTLER ,  Dale L. BOGER ,  The Scripps Research Institute ,  The Board of Regents of the University of Texas System

Inventor： Bruce Beutler ,  Dale L. Boger

IPC: C07D403/10 ,  A61P37/04

Abstract: A diprovocim compound that corresponds in structure to structural Formula V is disclosed, wherein A, W, Z, R1, R2, R3 and R4 (when present) are defined within. A diprovocim compound has immune-adjuvant properties on human and mouse cells in culture and on in vivo immunization of mice. A composition containing a diprovocim and a method of using a compound are also disclosed. A The immunostimulatory activity of a diprovocim compound is similar to that of LPS, to which there is no apparent structural similarity. A contemplated compound bears no structural similarity to either the TLR1/TLR2 lipoprotein agonists nor to any other synthetic TLR agonist, and is remarkably easy to prepare and synthetically modify.

公开(公告)号：US10697080B2

公开(公告)日：2020-06-30

申请号：US15572321

申请日：2016-05-06

Applicant: The Board of Regents of The University of Texas System

Inventor： Allen J. Bard ,  Huayi Yin

IPC: C25D3/66 ,  C25D9/04 ,  H01L21/02 ,  H01L31/18 ,  C25D9/08 ,  C25B1/00 ,  C25D21/12 ,  H01L21/66 ,  H01L31/0445 ,  H01L31/068

Abstract: Photoactive silicon films may be formed by electrodeposition from a molten salt electrolyte. In an embodiment, SiO2 is electrochemically reduced in a molten salt bath to deposit silicon on a carbonaceous substrate.